# Linagliptin Add-on to Insulin Background Therapy

> **NCT02897349** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 206 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** placebo
- **DRUG:** linagliptin
- **DRUG:** background therapy

## Key facts

- **NCT ID:** NCT02897349
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-30
- **Primary completion:** 2019-01-11
- **Final completion:** 2019-01-18
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2020-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02897349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02897349, "Linagliptin Add-on to Insulin Background Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02897349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*